The HTA review remains shrouded in secrecy, with brief and vaguely worded agendas released after meetings are held, no communiqués published for the past seven meetings, and organisations in other countries knowing more about the options under consideration and seeming to have more input than the Australian community.
But for a few selected insiders, the HTA review is a 'bin fire' of non-transparency
September 11, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The industry walked out on Britain, and what it cost to win them back
October 22, 2026 - - Latest News -
BioNTech opens mRNA plant, putting Melbourne's north on the biotech map
October 22, 2026 - - Latest News -
An architect of the first industry–Commonwealth medicines pact to lead CSL
October 21, 2026 - - Latest News -
Quarterly update shows Telix holds course for a US$1 billion milestone year
October 21, 2026 - - Latest News -
Chemist Warehouse keeps growing as Sigma sets its sights on oral GLP-1s
October 21, 2026 - - Latest News -
America's ever rising GLP-1 curve and how Australia is following
October 21, 2026 - - Latest News -
Patient groups across Asia-Pacific push for a say on medicine prices
October 21, 2026 - - Latest News
